Chen Z, et al. – The purpose of this investigation was to gauge the biologic agents targeting interleukin–23 and interleukin–17 for moderate–to–severe psoriasis. The findings displayed that ustekinumab targeted interleukin–23/interleukin–12p40; risankizumab, guselkumab, and tildrakizumab targeted interleukin–23p19; secukinumab and ixekizumab targeted interleukin–17A. It was noted that brodalumab targeted the interleukin–17 receptors. These agents demonstrated good efficacy in treating moderate–to–severe psoriasis.